Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Regression of a cardiac rhabdomyoma in a patient receiving everolimus.

Tiberio D, Franz DN, Phillips JR.

Pediatrics. 2011 May;127(5):e1335-7. doi: 10.1542/peds.2010-2910. Epub 2011 Apr 4.

PMID:
21464184
2.

Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.

Doğan V, Yeşil Ş, Kayalı Ş, Beken S, Özgür S, Ertuğrul İ, Bozkurt C, Örün UA, Karademir S.

J Trop Pediatr. 2015 Feb;61(1):74-7. doi: 10.1093/tropej/fmu056. Epub 2014 Oct 24.

PMID:
25344617
3.

Prenatal diagnosis of giant cardiac rhabdomyoma in tuberous sclerosis complex: a new therapeutic option with everolimus.

Mlczoch E, Hanslik A, Luckner D, Kitzmüller E, Prayer D, Michel-Behnke I.

Ultrasound Obstet Gynecol. 2015 May;45(5):618-21. doi: 10.1002/uog.13434.

4.

Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex.

Goyer I, Dahdah N, Major P.

Pediatr Neurol. 2015 Apr;52(4):450-3. doi: 10.1016/j.pediatrneurol.2015.01.004. Epub 2015 Jan 14.

PMID:
25682485
5.

Rapid resolution of cardiac rhabdomyomas following everolimus therapy.

Choudhry S, Nguyen HH, Anwar S.

BMJ Case Rep. 2015 Dec 9;2015. pii: bcr2015212946. doi: 10.1136/bcr-2015-212946.

6.

Everolimus-induced near-resolution of giant cardiac rhabdomyomas and large renal angiomyolipoma in a newborn with tuberous sclerosis complex.

Colaneri M, Quarti A, Pozzi M.

Cardiol Young. 2016 Jun;26(5):1025-8. doi: 10.1017/S1047951116000421. Epub 2016 Apr 8.

PMID:
27055516
7.

Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.

MacKeigan JP, Krueger DA.

Neuro Oncol. 2015 Dec;17(12):1550-9. doi: 10.1093/neuonc/nov152. Epub 2015 Aug 19. Review.

8.

Possible prevention of tuberous sclerosis complex lesions.

Kotulska K, Borkowska J, Jozwiak S.

Pediatrics. 2013 Jul;132(1):e239-42. doi: 10.1542/peds.2012-3607. Epub 2013 Jun 3.

9.

Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Kotulska K, Chmielewski D, Borkowska J, Jurkiewicz E, Kuczyński D, Kmieć T, Łojszczyk B, Dunin-Wąsowicz D, Jóźwiak S.

Eur J Paediatr Neurol. 2013 Sep;17(5):479-85. doi: 10.1016/j.ejpn.2013.03.002. Epub 2013 Apr 6.

PMID:
23567018
10.

Is mTOR inhibition a systemic treatment for tuberous sclerosis?

Moavero R, Coniglio A, Garaci F, Curatolo P.

Ital J Pediatr. 2013 Sep 17;39:57. doi: 10.1186/1824-7288-39-57. Review.

11.

[Rapamycin in the treatment of cardiac rhabdomyoma associated with tuberous sclerosis complex].

Pang LY, Zou LP, Huang LL, Gao Y, Ma SF, Zhang MN, Wang YY.

Zhonghua Er Ke Za Zhi. 2016 Jun 2;54(6):424-7. doi: 10.3760/cma.j.issn.0578-1310.2016.06.007. Chinese.

PMID:
27256228
12.

Rapamycin and rapalogs for tuberous sclerosis complex.

Sasongko TH, Ismail NF, Zabidi-Hussin Z.

Cochrane Database Syst Rev. 2016 Jul 13;7:CD011272. doi: 10.1002/14651858.CD011272.pub2. Review.

PMID:
27409709
13.

Oral everolimus treatment in a preterm infant with multifocal inoperable cardiac rhabdomyoma associated with tuberous sclerosis complex and a structural heart defect.

Mohamed I, Ethier G, Goyer I, Major P, Dahdah N.

BMJ Case Rep. 2014 Nov 26;2014. pii: bcr2014205138. doi: 10.1136/bcr-2014-205138.

14.

Everolimus tablets for patients with subependymal giant cell astrocytoma.

Turner SG, Peters KB, Vredenburgh JJ, Desjardins A, Friedman HS, Reardon DA.

Expert Opin Pharmacother. 2011 Oct;12(14):2265-9. doi: 10.1517/14656566.2011.601742. Epub 2011 Aug 1. Review.

15.

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S.

Lancet. 2013 Jan 12;381(9861):125-32. doi: 10.1016/S0140-6736(12)61134-9. Epub 2012 Nov 14. Erratum in: Lancet. 2013 Jan 12;381(9861):116.

PMID:
23158522
16.
17.

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study.

Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Berkowitz N, Anak O, Niolat J, Jozwiak S.

Lancet Oncol. 2014 Dec;15(13):1513-20. doi: 10.1016/S1470-2045(14)70489-9. Epub 2014 Nov 10.

PMID:
25456370
18.

[Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].

Mateos-González ME, López-Laso E, Vicente-Rueda J, Camino-León R, Fernández-Ramos JA, Baena-Gómez MA, Peña-Rosa MJ.

Rev Neurol. 2014 Dec 1;59(11):497-502. Spanish.

19.

Everolimus treatment of a newborn with rhabdomyoma causing severe arrhythmia.

Öztunç F, Atik SU, Güneş AO.

Cardiol Young. 2015 Oct;25(7):1411-4. doi: 10.1017/S1047951114002261.

PMID:
26339757
20.

Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.

Curran MP.

Paediatr Drugs. 2012 Feb 1;14(1):51-60. doi: 10.2165/11207730-000000000-00000. Review.

PMID:
22136276

Supplemental Content

Support Center